Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) shares were down 3.1% on Thursday . The stock traded as low as $8.40 and last traded at $8.65, with a volume of 1,262,019 shares traded. The stock had previously closed at $8.93.

Several research analysts have weighed in on ACHN shares. Zacks Investment Research raised shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $10.00 target price for the company in a research note on Tuesday, April 26th. Leerink Swann reaffirmed a “market perform” rating and set a $9.00 target price (up previously from $7.00) on shares of Achillion Pharmaceuticals in a research note on Wednesday, May 4th. Robert W. Baird reaffirmed an “outperform” rating and set a $10.00 target price on shares of Achillion Pharmaceuticals in a research note on Monday, June 6th. Chardan Capital started coverage on shares of Achillion Pharmaceuticals in a research note on Thursday. They set a “sell” rating and a $4.00 target price for the company. Finally, Jefferies Group reaffirmed a “hold” rating on shares of Achillion Pharmaceuticals in a research note on Thursday, May 5th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $9.63.

The firm’s market capitalization is $1.18 billion. The company’s 50-day moving average is $8.86 and its 200-day moving average is $8.08.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.01. During the same period in the prior year, the company earned ($0.17) earnings per share. On average, equities research analysts expect that Achillion Pharmaceuticals Inc. will post ($0.65) EPS for the current year.

Other hedge funds have added to or reduced their stakes in the company. Marshall Wace LLP raised its stake in Achillion Pharmaceuticals by 36.8% in the fourth quarter. Marshall Wace LLP now owns 970,862 shares of the biopharmaceutical company’s stock worth $10,476,000 after buying an additional 261,007 shares during the period. Morgan Stanley raised its stake in Achillion Pharmaceuticals by 738.4% in the fourth quarter. Morgan Stanley now owns 233,221 shares of the biopharmaceutical company’s stock worth $2,517,000 after buying an additional 205,405 shares during the period. Swiss National Bank raised its stake in Achillion Pharmaceuticals by 6.8% in the fourth quarter. Swiss National Bank now owns 152,400 shares of the biopharmaceutical company’s stock worth $1,644,000 after buying an additional 9,700 shares during the period. ProShare Advisors LLC raised its stake in Achillion Pharmaceuticals by 10.1% in the fourth quarter. ProShare Advisors LLC now owns 126,923 shares of the biopharmaceutical company’s stock worth $1,370,000 after buying an additional 11,681 shares during the period. Finally, Rhumbline Advisers raised its stake in Achillion Pharmaceuticals by 14.0% in the fourth quarter. Rhumbline Advisers now owns 117,525 shares of the biopharmaceutical company’s stock worth $1,268,000 after buying an additional 14,425 shares during the period.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.